Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Meningioma

• Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
• Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
• Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
• A Study of ONC201 for Refractory Meningioma
• Cabozantinib for Patients With Recurrent or Progressive Meningioma
• Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
• Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection
• Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
• NEO100 and High-Grade Meningioma
• Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
• Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function
• Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
• Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
• The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
• Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults
• Tranexamic Acid Reduce Blood Loss in Meningioma Resection
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
• Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
• Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
• 9-ING-41 in Pediatric Patients With Refractory Malignancies.
• Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
• Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
• Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™
• Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
• Magnesium and Intraoperative Blood Loss in Meningioma Surgery
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
• Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
• Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
• Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
• Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
• A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
• S9005 Mifepristone in Meningioma
• Dosimetry Guided PRRT With 90Y-DOTATOC
• 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
• AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
• An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
• Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
• Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
• Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• Trabectedin for Recurrent Grade II/III Meningioma
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
• A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery
• Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
• Efficacy of Tranexamic Acid in Brain Tumor Resections
• Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
• Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
• Cellular Immunotherapy Study for Brain Cancer
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
• Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
• Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
• Monthly SOM230C for Recurrent or Progressive Meningioma
• Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
• Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
• Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
• Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
• Imatinib Mesylate in Treating Patients With Recurrent Meningioma
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
• Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
• Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
• Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
• Irinotecan in Treating Children With Refractory Solid Tumors
• S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
• Antineoplaston Therapy in Treating Patients With Meningioma
• S9624 Ifosfamide in Treating Patients With Meningeal Tumors